Uniportal robotic-assisted minimally invasive esophagectomy is a safe option for esophageal cancer patients, showing strong early outcomes.

• Complete resection achieved in 95% of cases, with low conversion rate (5%).
• Median operative time was 155 minutes with an average blood loss of 450 ml.

Consider this technique for suitable patients, as it supports quicker recovery and less postoperative pain.

• Clavien-Dindo complications were noted in 29%, but no 90-day mortality was reported.

Intraoperative quantitative blood flow measurement significantly reduces anastomotic leakage in esophageal cancer surgery.

• Patients using SPY-QP imaging had lower overall complication rates and less postoperative leakage.
• They experienced a shorter hospital stay and less intraoperative blood loss.

Quantitative assessment helps optimize anastomotic site selection, improving patient outcomes.

• The quantitative group had more preoperative chemotherapy and specific anastomotic techniques, enhancing results.

One-third of patients with locally advanced esophageal cancer show a complete clinical response to neoadjuvant chemoradiotherapy, but managing uncertain responses is critical for surgical success.

• Only 15% of patients with uncertain tumor response achieved a complete pathological response after esophagectomy.
• Complete response rates varied: 26% for non-traversable lesions, 10% for high-grade dysplasia, and 8% for those with clinical suspicion of residual tumor.
• Notably, squamous cell carcinoma patients with non-traversable lesions had the highest complete response rate (33%).

Surgeons should recommend esophagectomy for most patients with uncertain responses, as 85% will have residual disease.